Document:

Exhibit 10.37

MASTER
CLINICAL SERVICES AGREEMENT

between

URIGEN HOLDINGS, INC.

and

CLINIMETRICS RESEARCH CANADA, INC.

This Master Services
Agreement (this “Agreement”) is made as of October 4, 2005 by and between
Urigen, Inc., a Canadian corporation with offices located at Urigen Holdings,
Inc., 515 West Hastings Street, Suite 7100, Vancouver, BC V6B 5K3, Canada (“Urigen”)
and Clinimetrics Research Canada, Inc., an Ontario corporation with offices at
2655 North Sheridan Way, Suite 120, Mississauga, Ontario L5K2P8, Canada (“Service
Provider”).

WITNESSETH

WHEREAS, Urigen has now
and from time to time in the future may have the desire to engage Service
Provider for research or clinical services and

WHEREAS, Service Provider
would like to provide such services on the terms and conditions set forth
herein.

NOW THEREFORE, in
consideration of the premises and of the mutual promises and covenants herein
contained, the adequacy of which is acknowledged by each of the parties, the
parties hereto agree as follows:

1.             SERVICES
AND PERSONNEL

1.1           General.   Service
Provider shall use its best efforts to provide the services reasonably helpful
for the successful completion of each project (“Project”) set forth in a Work
Order (“Services”) to Urigen in accordance with this Agreement, to keep Urigen
fully advised of the progress of the work, to provide Urigen with such reports,
specifications, and the like, as requested by Urigen.

1.2           Work
Order.   Services provided by Service Provider shall be subject to the
terms and conditions of this Agreement. All such Services shall be the subject
of a work order, substantially in the form of Exhibit A, setting forth
the following with respect to the applicable Project: (i) description of
Services to be provided, (ii) fee and payment schedule for the Services, (iii)
description of deliverables to be delivered by Service Provider (each, a “Deliverable”)
and their intended use, (iv) materials to be provided by each party and (v) a
Project timeline. After a work order substantially in the form of Exhibit A
is agreed upon and executed by the parties hereto, the same shall be attached
to this Agreement as an amendment to Exhibit B (each, a “Work Order”)
and the Work Order shall then be a part of this Agreement. There will be no
limit to the number of Work Orders that may be added to this Agreement.
Services shall only be commenced after the execution of a Work Order.

1.3           Change
Orders.   In the event that Service Provider is requested or required
to perform services that are outside the scope of this Agreement, such services
and a compensation schedule therefore must be mutually agreed upon by the
parties in a written change order (“Change Order”) prior to the provision of
said services. The Change Order constitutes an amendment to the applicable Work
Order and the services set forth therein shall be deemed to be Services part of
such Work Order.

1.4           Project
Manager.   An employee of Service Provider who is acceptable to Urigen
shall be appointed as project manager by Service Provider (the “Project Manager”).
The Project Manager shall be the primary contact for Urigen and shall timely
address all issues and concerns raised by Urigen, as well as provide to Urigen
all information requested by Urigen concerning this Agreement or the Services.
The Project Manager shall not be replaced without the prior written consent of
Urigen. In the event that Service Provider becomes aware that the Project Manager
plans to leave the employment of Service Provider or shall be unable to
complete the Services due to dismissal, death or disability, it shall give
immediate written notice of the same to Urigen. Should Urigen not be satisfied
with the services of Project Manager, Urigen may give notice of the same to
Service Provider. If Service Provider and Urigen are unable to mutually agree
upon a substitute Project Manager within a period of fifteen (15) days
following notice delivered pursuant to either of the two foregoing sentences,
this Agreement may be immediately terminated by Urigen upon written notice to
Service Provider.

1.5           Nonconforming
Services.   Notwithstanding anything to the contrary herein, if Service
Provider provides any deliverable or Services that fail to conform in any
material respect to the specifications of Urigen, including those set forth in
the applicable Work Order and any written instructions of Urigen, in addition
to any rights or remedies Urigen may have available to it, Urigen may require
Service Provider to (i) conform such Services to the specifications of Urigen
at no additional cost to Urigen or (ii) if Service Provider does not or cannot
promptly conform such Services, credit to Urigen any monies paid by Urigen to
Service Provider for the performance of such Services and the additional cost
incurred by Urigen in connection with causing the Services to conform to the
relevant specifications of Urigen.

1.6           Service
Provider Personnel.   All employees and agents of Service Provider that
perform Services under this Agreement are employees and agents, respectively,
of Service Provider and not Urigen during the term of this Agreement and shall
at all times be directed solely by Service Provider. Notwithstanding Urigen’s
obligation to reimburse certain costs pursuant to Section 3 hereof, Service
Provider will bear and pay (i) all salaries, wages, benefits and other
compensation which its employees or agents may be entitled to receive for
performing Services and (ii) all reimbursable travel, lodging and other
expenses which the employees or agents may be entitled to receive for
performing Services. Service Provider will be solely responsible for
withholding and paying all applicable payroll taxes of any nature, including
social security and other social welfare taxes or contributions, that may be
due on amounts paid to employees or agents. To the extent that any Services are
performed on the premises of Urigen, Service Provider will cause each of its
employees and agents involved in providing any Services to Urigen to comply
with Urigen’s then-current workplace rules, security procedures and
confidentiality policies and procedures for the Urigen facility where such
employee or agent performs Services.

 

 2

1.7           Subject
Enrollment.   To the extent applicable to a particular Project, Service
Provider shall exercise all reasonable diligence to meet and maintain subject
enrollment rates set forth in a Work Order. Urigen shall have the right to
terminate performance under a Work Order if enrollment rates do not reach and
maintain levels agreed in the Work Order. Any such termination shall be deemed
a termination by Urigen pursuant to Section 6.2(a)(ii).

2.             REPRESENTATIONS,
WARRANTIES AND COVENANTS

Service
Provider represents, warrants and covenants to Urigen as follows.

2.1           Formation/Power
and Authority.   Service Provider is duly formed and validly existing
under the laws of its jurisdiction of formation and has all requisite power and
authority, in each jurisdiction in which Services will be performed, to own and
operate its business and properties and to carry on its business as such
business is now being conducted and to execute and deliver this Agreement and
to perform its obligations hereunder.

2.2           No
Conflict.   The execution, delivery and performance of this Agreement
by Service Provider and the consummation of the transactions contemplated
hereby do not and will not contravene the formation documents of Service
Provider and do not and will not conflict with or result in a breach of or
default under any agreement to which it is a party that would have a material
adverse affect Service Provider’s ability to perform its obligations under this
Agreement.

2.3           Compliance
with Applicable Law.   Service Provider represents and warrants that is
in full compliance at all times and will continue to be in compliance at all
times with all applicable Canadian or foreign laws, rules, regulations,
guidelines and industry standards, including but not limited to those of the
U.S. Food and Drug Administration (the “FDA”); good clinical practice
guidelines of the FDA; the Food and Drug Act (Canada), ICH Harmonized
Tripartite Guideline and the regulations promulgated pursuant thereto; and any
other relevant Canadian or foreign regulatory or governmental authority (“Applicable
Law”).

2.4           Pursuant
to Health Canada Therapeutics Division (TPD) regulations and/or the guidelines
described in the Declaration of Helsinki, ICH Good Clinical Practice:
Consolidated Guideline, Tri-Council Policy Statement, Ethical Conduct for
Research Involving Humans, and Urigen requirements for the conduct of clinical
studies, as applicable, and solely with respect to those Services described in
the applicable Work Order, Urigen hereby transfers and delegates to Service
Provider the responsibilities of a sponsor in the conduct of clinical
investigations pursuant to regulations of the TPD. Service Provider accepts
such delegation, agrees to carry out diligently all transferred obligations, agrees
to satisfy or comply with the delegated responsibility, and agrees to maintain
accurate and complete records sufficient to document such compliance for a
period at least equal to applicable government regulations and Urigen
requirements.

2.5           Report
of Noncompliance.   Should noncompliance of an employee, agent,
investigator or study site with Applicable Law, this Agreement or any
applicable agreement be discovered by or come to the attention of Service
Provider, Service Provider will immediately notify Urigen and

 3
 

appropriate action will be taken by Service Provider at the direction
of Urigen. Any such action shall be taken after consultation with Urigen.

2.5           Experience/Timeliness.   Service
Provider, its employees and agents, have and will continue to have the
knowledge, experience and skill to provide, and will provide, the Services in a
professional and timely manner.

2.6           Workmanship.   Services
will conform to the highest standards of workmanship and the specifications for
the Project.

2.7           Performance.   Service
Provider will perform all Services in accordance with this Agreement,
Applicable Law, each applicable protocol (each, a “Protocol”), standard
operating procedures approved by Urigen and the instructions of Urigen.

2.8           Deliverables.   Except
with respect to data and information over which Service Provider has no
reasonable control, each Deliverable delivered in connection herewith shall be
suitable for its intended use.

2.9           Permits.   Prior
to commencement of a Project, to the extent applicable to a particular Project,
Service Provider will identify all permits and approvals necessary or helpful
in connection with the conduct and successful completion of such Project. The
parties shall indicate in the Work Order which party will be responsible for
procuring and maintaining each such permit and approval. Unless impossible,
expressly prohibited by Applicable Law or otherwise requested by Urigen in
writing, Service Provider shall procure and maintain in the name of Urigen all
permits and approvals for which it is responsible.

2.10         No
Encumbrance.   Service Provider hereby (i) acknowledges and agrees that
neither it, nor any of its affiliates or subsidiaries, nor any of its or their
directors, officers, employees and agents has any interest in Urigen Data or
Inventions (each as defined below) and (ii) covenants that it will not lien or
encumber, or otherwise cause, permit or consent to the granting of a lien or
encumbrance of the Urigen Data or Inventions.

2.11         Debarment.   Service
Provider hereby certifies it does not and shall not employ, contract with or
retain any person directly or indirectly to perform Services under this
Agreement if such person is debarred under 21 U.S.C. 335a (a) or (b) or other
equivalent laws, rules, regulations or standards of any other relevant jurisdiction.
Upon written request of Urigen, Service Provider shall, within ten (10)
business days, provide written confirmation that it has complied with the
foregoing obligation. Service Provider agrees to immediately disclose in
writing to Urigen if any employee or agent is debarred, or if any action or
investigation is pending or, to the best of Service Provider’s knowledge,
threatened, relating to the debarment of Service Provider or any person
performing services related to this Agreement.

2.12         Disclosures.   Service
Provider shall also provide all information to Urigen requested by Urigen to
comply with any disclosure requirements of Applicable Law, including any
information required to be disclosed in connection with any financial
relationship between Urigen and Service Provider. Service Provider shall
disclose to Urigen any financial interest,

 4
 

other than the payment for Services agreed to
hereunder, that Service Provider might have in any Project.

2.13         Inspections.   Service
Provider agrees to permit representatives of the FDA or any other relevant
regulatory or governmental authority to access at any reasonable time during
normal business hours relevant records, information (and where applicable make
copies of the same), personnel and facilities relating directly or indirectly
to this Agreement or any Services.

2.14         Scheduling
of Inspections.   Service Provider shall immediately notify Urigen if
the FDA or other governmental authority schedules, or without scheduling begins,
an inspection or audit relating directly or indirectly to this Agreement or any
Services. Service Provider shall make every reasonable effort to permit Urigen
to be present at or participate in such inspection or audit if the same relates
directly or indirectly to this Agreement or Services. In addition, Service
Provider will immediately provide Urigen copies of any correspondence from or
to the FDA or other regulatory authorities relating directly or indirectly to
this Agreement or any Services.

3.             COMPENSATION

3.1           The
budget and compensation to be paid to Service Provider for the Services are
contained in each Work Order. Service Provider acknowledges that it has
included all of its costs, fees and expenses, including administrative
overhead, in calculating the fee for the Services budget attached hereto as
part of the applicable Work Order and that Urigen shall not be liable for any
other costs, fees or expenses of Service Provider. Payments will be made
payable in U.S. dollars to Service Provider at the address above. Unless
otherwise agreed in the Work Order, invoices shall be submitted by Service
Provider to Urigen on a monthly basis and, except with respect to amounts
subject to a bona fide dispute, payment will be made by Urigen within thirty (30)
days after Urigen’s receipt of Service Provider’s monthly invoice. If payment
to Service Provider is not received within thirty (30) days of receipt of an
invoice by Urigen, Service Provider may charge Urigen monthly late fees in the
amount of 1%. All income taxes, GST, levies, surcharges or other similar
charges and any penalties levied thereon which relate to any amounts paid to
Service Provider hereunder shall be the responsibility of and paid by the
Service Provider. No line item in any budget shall be exceeded by Service
Provider without the prior written consent of the Urigen. All pass-through
costs will be at actual cost with no mark-up for administrative fees, overhead
or other similar fees.

3.2           Upon
written acceptance any Work Order, Urigen shall provide a pre-payment to
Service Provider (“Pre-Payment Fee”) in an amount agreed to by the parties.

3.3           Should
the research be cancelled, delayed for greater than 30 days or scoped down
(defined as decrease to the original agreed budget by 50% or greater), for
reasons beyond the reasonable control of Service Provider and Urigen request
that the Project team remain available during such period, Urigen shall
continue to pay all expenses as agreed upon in the Work Order for dedicated
Service Provider personnel or in the alternative, the parties may negotiate the
reassignment of dedicated Service Provider personnel. Any amounts payable by
Urigen hereunder shall be reduced by the value of services provided by Project
team members to other clients of Service Provider during the relevant period.

 

 5

4.             URIGEN
DATA, PREEXISTING TECHNOLOGY AND INVENTIONS

4.1           Ownership
of Urigen Data and Inventions.   All (i) data, images, information,
documents, records in whatever form obtained, developed, recorded or compiled
in connection with this Agreement or any Work Order (“Urigen Data”) and (ii)
technology, inventions (whether patentable or not), discoveries and
improvements relating to a relevant study, protocol, the study drug and its use
or otherwise developed or conceived in connection with this Agreement or the
Services (“Inventions”) are and shall remain the sole and exclusive property of
Urigen. Service Provider shall immediately deliver any such property to Urigen.
Service Provider and the Project Manager agree that they will not file any
patent applications with respect to any Urigen Data or Invention.

4.2           Preexisting
Technology.   It is recognized and understood that the other pre-existing
inventions and technologies of Urigen or Service Provider are their separate
property, respectively, and are not affected by this Agreement.

4.3           With
respect to all Urigen Data and Inventions, Service Provider and Project Manager
agree (i) to disclose the same promptly to Urigen; (ii) to execute documents
evidencing the rights set forth herein; and (iii) upon the request of Urigen
and at the sole expense, discretion and exclusive control of Urigen, to apply,
or to assist and cooperate with Urigen in applying for, letters patent or like
corresponding legal protection of any such Urigen Data and Inventions in the
United States and all foreign countries (and for any extension, continuation,
validation, reissue or renewal thereof). For that purpose, Service Provider and
Project Manager agree to execute, and Urigen agrees to cause its employees and
agents to execute, all papers necessary therefor, including assignments to
Urigen or its nominee, without consideration, and also agree without further
consideration, but at Urigen’s expense, to provide such information as may be
required by Urigen and to assist Urigen, or its agents or designees, in the
preparation and prosecution of any such patent application, the enforcement of
any such resulting patent and the protection of any such invention or
discovery.

4.4           The
obligations imposed by this Section 4 shall survive the expiration or earlier
termination, for any reason, of this Agreement.

5.             CONFIDENTIALITY/PUBLICATIONS

5.1           Confidential
Information.   Neither party shall, at any time, without the disclosing
party’s prior written consent, disclose to any third party any of the
disclosing party’s Confidential Information or the fact that the Services are
being conducted on behalf of Urigen. The receiving party shall use such
Confidential Information solely for the purposes for which the disclosing party
provided it. The receiving party shall keep such information secure, secret and
confidential and cause its directors, officers, employees, or agents to keep
such information secure, secret and confidential and shall take all reasonable
precautions to prevent any unauthorized use or disclosure of the Confidential
Information. For purposes of this Agreement, “Confidential Information” means
any information of the disclosing party in any form, whether of a technical,
business or other nature, including but not limited to, information, documents,
data and images which (i) relate to the disclosing party’s trade secrets,
products, promotional material,

 6
 

developments, proprietary rights or business affairs,
(ii) with respect to Urigen only, relate to or are part of Urigen Data or
Inventions, (iii)  with respect to
Urigen only, are developed by or compiled by Service Provider pursuant hereto,
and (iv) were exchanged by the parties prior to the date hereof. Confidential
Information does not include any information that:

(a)   the
receiving party can prove (with written documentation) was known to it prior to
the date of this Agreement and any other agreement between the parties hereto;

(b)   the
receiving party can prove was lawfully obtained from a third party without any
obligation of confidentiality; or

(c)   is
or becomes part of the public domain through no act or violation of any
obligation of the receiving party.

5.2           Required
Disclosure.   Notwithstanding anything to the contrary in section 5.1
above:

(a)   if
the receiving party is required by Applicable Law to disclose Confidential
Information to a third party, the receiving party shall notify the disclosing
party, and the receiving party and the disclosing party shall agree to a
mutually satisfactory way to disclose such information as necessary and in
accordance with Applicable Law and

(b)   with
respect to research subjects’ medical records, the parties agree to hold in confidence
the identity and personal health information of the patients in accordance with
Applicable Law.

5.3           Return
of Confidential Information.   Upon expiration of this Agreement,
completion of a Work Order, earlier termination of a Work Order or this Agreement,
or otherwise upon the request of the disclosing party, the receiving party will
promptly, at the disclosing party’s expense (i) provide a copy of all relevant
Confidential Information to the disclosing party in a form acceptable to the
disclosing party and (ii) to the extent that the disclosing party so requests,
provide to the disclosing party or destroy all other copies of relevant
Confidential Information in the receiving party’s possession or under the
receiving party’s control, except as otherwise required by Applicable Law. The
receiving party will not withhold from the disclosing party any Confidential
Information as a means of resolving any dispute. Service Provider will not
utilize Confidential Information for any purpose other than that of rendering
the Services.

5.4           Publications.   Service
Provider shall have no right to publish any Confidential Information.

5.5           Handling
and Reconstruction of and Access to Confidential Information.   Service
Provider will establish and maintain rigorous safety and facility procedures,
data security procedures and other safeguards against the destruction, loss, or
alteration of Confidential Information in the possession of Service Provider.
Service Provider will be responsible for developing and maintaining procedures
for the recovery and reconstruction of lost Confidential Information. Service
Provider will correct or remedy, at Urigen’s request and sole discretion and at
no charge to Urigen, any destruction, loss or alteration of any Confidential
Information that occurs while such Confidential Information is under the
control or supervision of Service

 7
 

Provider, its employee or agents (including permitted
subcontractors). Upon reasonable request by Urigen at any time, Service
Provider will promptly retrieve, in the format and on media acceptable to Urigen,
any portion of Confidential Information reasonably specified by Urigen. Urigen
will have unrestricted access to, and the right to review and retain the
entirety of, all computer or other files containing Confidential Information.
At no time will any of such files or other materials or information be stored
or held in a form or manner not immediately accessible to Urigen. Service
Provider shall not withhold from Urigen any Confidential Information in order
to settle a dispute.

5.6           To
the extent that either party hereto collects, uses and discloses personal
information in connection with this Agreement, each such party warrants that it
and/or its designee will adhere to and comply with applicable laws and
regulations regarding privacy and protection of personal information including,
but not limited to, Canada’s Personal
Information Protection and Electronic Documents Act (“PIPEDA”). For
the purpose hereof, personal information includes, without limitation, all
personal information of patients, staff, students or volunteers that the
Institution collects, uses or discloses in the course of its business,
corporate activities and research. Subject to further obligations under PIPEDA
and other applicable privacy legislation, each Party agrees to (i) designate an
individual or individuals, or ensure that an individual or individuals has been
designated, to be accountable for its compliance with PIPEDA and other
applicable privacy legislation; (ii) limit its use of any personal information
for purposes specified in this Agreement and in the consent provided by the
applicable Study subject, or as prescribed by law; (iii) use appropriate
security safeguards to protect the personal information from unauthorized
access or use; (iv) make or cause to be made available upon request, as
required by the other party hereto to ensure compliance with PIPEDA and other
applicable privacy legislation, all books, documents and records (including
electronic records) relating to the transferred personal information and the
methods implemented to safeguard the personal information; and (v) notify the
other party hereto in writing immediately upon becoming aware of any
non-compliance with, or breach of, the terms of this provision or obligations
under PIPEDA or other applicable privacy legislation, in which case the party
in breach shall consult with the other party regarding the actions it intends
to take to remedy the breach and shall subsequently implement such actions,
taking into consideration any recommendations given by the other party in
connection therewith. No party hereto shall transfer or disclose personal
information collected under this Agreement to any third parties without prior
written consent from the other party hereto, in which case the disclosing or
transferring party shall obligate any such third parties to comply with the
terms and conditions hereof.

6.             TERM
AND TERMINATION

6.1           Term.   The
term of this Agreement shall begin on the date first above mentioned and shall
end three (3) year(s) thereafter, unless sooner terminated in accordance with
the terms hereof. The term of this Agreement may be extended upon written
agreement by Urigen and Service Provider.

6.2           Termination.

 

 8

(a)   A Work Order or this Agreement may be
terminated (i) by Urigen at any time in the exercise of its sole discretion
upon prior written notice to Service Provider, (ii) by a party upon the
material breach of this Agreement by the other party, which material breach
continues unremedied for thirty (30) days after delivery to the breaching party
by the nonbreaching party of notice of the material breach, (iii) by a party
immediately in the event of the bankruptcy (voluntary or otherwise), insolvency
or other similar financial distress of the other party, (iv) by Urigen pursuant
to Section 1.4, or (v) by a party or the parties pursuant to Section 11.13.

(b)   Upon
termination or expiration, Service Provider shall (i) promptly terminate all
Services, provided that Service Provider shall not immediately terminate
Services helpful in connection with responsible treatment of any study subjects
and (ii) Service Provider will work with Urigen to transition the relevant
Services to Urigen or its designee. In the event of a termination by Urigen
pursuant to Section 6.2(a)(i) or by Service Provider pursuant to Section
6.2(a)(ii) or 6.2(a)(iii), the total sums payable by Urigen shall be equitably
pro-rated for actual Services satisfactorily completed by the date of such
termination, with any unexpended funds previously paid by Urigen to Service
Provider promptly refunded to Urigen. In the event of any other termination, the
parties shall negotiate in good faith to determine the appropriate amount to be
paid by Urigen to Service Provider (or refunded to Urigen by Service Provider,
as the case may be), in light of the circumstances of such termination, in
compensation for all Services rendered in accordance with this Agreement. Upon
the termination or expiration of a Work Order or this Agreement and in addition
to fulfilling the requirements of Section 5.3, Service Provider shall promptly
return to Urigen and at Urigen’s expense any unused study supplies, including
all unused study drug and placebo.

7.             AUDIT

Urigen and its agents and
designees shall have the right to audit Service Provider’s facilities, systems,
records (financial and otherwise), procedures, and documentation related to
this Agreement. In connection with any audit, Service Provider shall also
provide Urigen access to its personnel. Such audits may be conducted upon
reasonable notice during the term of this Agreement and for a period of up to
two (2) years after termination or expiration. In connection with a financial
audit, if the audit reveals that payments made by Urigen to Service Provider
for any period audited have not exceeded amounts owed by Urigen for such
period, Urigen shall pay the costs of such audit and Service Provider shall not
have any liability therefor. If the audit reveals that payments made by Urigen
to Service Provider for any period audited exceed amounts actually owed by
Urigen for such period, but by less than three percent (3%) of the amount
actually owed, Service Provider shall in addition to repaying any overpaid
amounts equally share with Urigen the reasonable costs of such audit work. If
the audit reveals that payments made by Urigen to Service Provider for any
period audited exceed amounts actually owed by Urigen for such period by three
percent (3%) or more of the amount actually owed, Service Provider shall in
addition to repaying any overpaid amounts pay the reasonable costs of such
audit work. In no event shall Urigen be liable to pay Service Provider’s costs
and expenses related to this Section.

 9
 

8.             ADVERSE
EVENTS

To the extent appropriate
with respect to Services to be delivered in connection with a given Work Order,
Service Provider shall have a system to identify and collect all serious
adverse experiences and unexpected adverse experiences, which shall include
instructing investigators to contact Service Provider and/or Urigen directly
within one business day of a serious adverse event. Service Provider will
notify Urigen by telephone by fax within one business day of its own receipt of
notice of any serious adverse event. Service Provider will promptly thereafter
follow-up with written documentation to Urigen. Service Provider shall notify
all study sites and investigators of any serious, unexpected adverse event as
required by Applicable Law, unless requested otherwise by Urigen. Adverse
events other than those described above will be submitted by Service Provider
in writing on case report forms during the course of the Study.

9.             INDEMNIFICATION

9.1           Urigen
shall indemnify, defend and hold harmless Service Provider and its directors,
officers, employees and agents (the “Service Provider Indemnitees”) against any
and all losses, costs, expenses and damages, including but not limited to
reasonable attorneys’ fees, resulting from (i) a personal injury caused by the
use of a study drug supplied by Urigen in connection with a Work Order or
Project, (ii) the material breach of this Agreement by Urigen or the mutual
breach by Urigen of any agreement with a study site or investigator directly
relevant to a Project, or (iii) the negligence or intentional misconduct of any
Urigen Indemnitee, except to the extent that such claim is caused by a Service
Provider Indemnitee’s negligence or malpractice, reckless or intentional
misconduct, or breach of this Agreement. Each Service Provider Indemnitee shall
fully cooperate and aid in such defense. Service Provider shall have the right
to select and to obtain representation by separate legal counsel at its own
expense. Notwithstanding anything to the contrary herein, Urigen shall have the
right to select counsel for, direct and control any proceedings related to any
of its study drugs at the expense of the indemnifying party.

9.2           Service
Provider shall indemnify, defend and hold harmless Urigen and its affiliates
and its and their respective directors, officers, employees and agents against
(the “Urigen Indemnitee’s) any and all losses, costs, expenses and damages,
including but not limited to reasonable attorneys’ fees, resulting from the (i)
material breach of this Agreement by Service Provider, including but not
limited to adherence to an applicable Protocol, Applicable Law or any
instructions or other directions given by Urigen or (ii) the negligence or
intentional misconduct of any Service Provider Indemnitee, except to the extent
that such claim is caused by a Urigen Indemnitee’s negligence or malpractice,
reckless or intentional misconduct, or breach of this Agreement. Subject to the
final sentence of Section 9.1, Service Provider shall have the right to defend
against such claim, including selection of counsel and control of the
proceedings, including reasonable settlement. Each Urigen Indemnitee shall
fully cooperate and aid in such defense. Urigen shall have the right to select
and to obtain representation by separate legal counsel at its own expense.

 10
 

10.           CONTRACTING/SUBCONTRACTING

All services or materials
for which Service Provider contracts, subcontracts or purchases for purposes of
this Agreement shall be subject to prior written approval by Urigen. Service
Provider hereby unconditionally guarantees the timely performance of Services
and delivery of Deliverables in accordance with this Agreement by any affiliate
or subcontractor hereunder.

11.           MISCELLANEOUS

11.1         Entire
Agreement.   This Agreement constitutes the entire agreement between
the parties and supersedes all prior negotiations, representations or
agreements, either written or oral, with respect to the subject matter hereof.

11.2         Publicity.   None
of the parties shall use the name of any other party for promotional purposes
without the prior written consent of the party whose name is proposed to be
used, nor shall either party disclose the existence or substance of this
Agreement except as required by Applicable Law. Notwithstanding the preceding,
the participation of Service Provider in the matters undertaken pursuant to
this Agreement may be recognized by Urigen in publications and promotional
materials that may result from the Services.

11.3         Governing
Law.   The laws of the province of Ontario shall govern this Agreement.

11.4         Independent
Contractor.   Service Provider, investigators recruited by Service
Provider, and research staff at study sites recruited by Service Provider are
acting in the capacity of independent contractors hereunder and not as
employees of Urigen.

11.5         Nonsolicitation.   In
the event that during the term of a Work Order and for six (6) months
thereafter, each party agrees not to solicit or hire any of the other party’s
employees who performed substantial work in connection with the Work Order or
relevant Project, provided this prohibition shall not apply to general
solicitations not specifically targeted at the other party’s employees.

11.6         Agreement
Modification/Assignment.   This Agreement, or any of its Exhibits, may
not be altered, amended, or modified except by a written document signed by the
parties hereto. Service Provider will not assign this Agreement or any of its
rights or obligations without the prior written consent of Urigen and any
purported assignment in contravention of this Section shall be null and void;
provided, however, that Urigen may assign this Agreement in connection with (i)
the sale, transfer or other disposition of its assets related to this
Agreement, (ii) a change in control of Urigen or (iii) the sale or transfer of
substantially all of Urigen’s outstanding stock.

11.7         Notice.   Any
notices given hereunder shall be sent by fax or email, with a confirmation copy
sent via overnight courier or via overnight courier to the following addresses
(or such other address as a party may designate as a notice address in a prior
written notice to the other party) and shall be deemed delivered when received
(or if received on a weekend or holiday, on the next business day thereafter)
as follows:

 

 11

	
  If to Urigen:

  	
   

  	
  Urigen Holdings, Inc.

  
	
   

  	
   

  	
  William Garner, MD., President

  
	
   

  	
   

  	
  515 West Hastings Street, Suite 7100

  
	
   

  	
   

  	
  Vancouver, British Columbia V6B 5K3

  
	
   

  	
   

  	
  Canada

  
	
   

  	
   

  	
  Tel: (604) 687-4742

  
	
   

  	
   

  	
  Fax: (604) 661-1730

  
	
   

  	
   

  	
  Email: bill@urigen.com

  
	
  If to Service

  	
   

  	
  Clinimetrics Research
  Canada, Inc.

  
	
  Provider:

  	
   

  	
  2655 North Sheridan Way, Suite 120,

  
	
   

  	
   

  	
  Mississauga, Ontario L5K2P8

  
	
   

  	
   

  	
  Canada

  
	
   

  	
   

  	
  Attention: Cheryl Talbot

  
	
   

  	
   

  	
  Tel: (905) 403-9901

  
	
   

  	
   

  	
  Fax: (905) 452-9083

  
	
   

  	
   

  	
  Email: ctalbot@clinimetrics.com

  

 

11.8         Counterparts.   This
Agreement may be executed in counterparts, each of which will be deemed an
original and both of which together will constitute one and the same
instrument.

11.9         Survival
of Obligations.   Notwithstanding expiration or termination of this Agreement
for any reason, rights and obligations, which by their nature should survive,
will remain in full force and effect. In particular Sections 1.5, 1.6, 2.4,
2.8, 2.10, 2.11, 2.12, 2.13, 2.14, 2.15, 2.16, 3, 4, 5, 6.2(b), 7, 9, 11.4,
11.7, 11.9, 11.11, 11.13 and 11.14 will survive the expiration or termination
of this Agreement.

11.10       Enforceability.   If
any of the provisions or a portion of any provision of this Agreement is held
to be unenforceable or invalid by a court of competent jurisdiction, the
validity and enforceability of the enforceable portion of any such provision
and/or the remaining provisions will not be affected thereby.

11.11       Insurance.   Service
Provider agrees to keep in full force and effect and maintain at its sole cost
and expense insurance coverage in types and amounts commensurate in its
industry for the performance of services substantially similar to the Services
by similarly sized service providers and as otherwise prudent or required by
law, which coverage will be placed with a first class insurer with at least an
A rating by Standard & Poor’s. Service Provider agrees to provide Urigen
with certificates of insurance if requested to do so by Urigen. Urigen agrees
to keep in full force and effect and maintain at its sole cost and expense
insurance coverage in types and amounts commensurate in its industry for the
conduct of clinical trials and as otherwise prudent or required by law, which
coverage will be placed with a first class insurer with at least an A rating by
Standard & Poor’s. Urigen agrees to provide Service Provider with
certificates of insurance if requested to do so by Service Provider.

 12
 

11.12       Force
Majeure.   If either party shall be delayed or hindered in or prevented
from the performance of any act required hereunder by reason of strike,
lockouts, labor troubles, restrictive governmental or judicial orders or
decrees, riots, insurrection, war, acts of God, inclement weather or other
reason or cause reasonably beyond such party’s control (each a “Disability”),
then performance of such act shall be excused for the period of such
Disability. The party incurring the Disability shall provide notice to the
other of the commencement and termination of the Disability. Should a
Disability continue for more than three (3) months, the party unaffected by the
Disability may terminate this Agreement upon prior written notice to the
affected party. Should the Disability equally affect the performance of both
parties, then such termination shall only be by mutual written agreement.

11.13       Third
Party Beneficiaries.   The provisions set forth in this Agreement are
for the sole benefit of the parties hereto and their successors and assigns,
and they shall not be construed as conferring any rights on any other persons.

11.14       Prior
Agreement.   Notwithstanding anything to the contrary in the CDA,
parties hereby agree that the CDA is terminated and superceded, including any
provisions that expressly or by implication survive termination, by this
Agreement as of the Effective Date.

*     *     *     *

 

 13

IN WITNESS WHEREOF, the
parties hereto have caused this Master Clinical Services Agreement to be
executed by their duly authorized representatives as of the date first above
written.

	
  URIGEN HOLDINGS, INC.

  	
   

  
	
   BY:

  	
   

  	
  /s/ Michael Flashner

  	
   

  
	
   

  	
   

  	
  Name:

  	
   

  	
  Michael Flashner

  	
   

  
	
   

  	
   

  	
  Title:

  	
   

  	
  Chief Operating Officer

  	
   

  
	
  CLINIMETRICS
  RESEARCH CANADA, INC.

  	
   

  
	
  BY: 

  	
   

  	
  /s/ James R. Wilson

  	
   

  
	
   

  	
   

  	
  Name: 

  	
   

  	
  James R. Wilson

  	
   

  
	
   

  	
   

  	
  Title: 

  	
   

  	
  Chief Business Officer

  	
   

  

 

GST TAX ID # 87342-8916
RT0001

 

EXHIBIT
A

WORK
ORDER #

Project
Code (Clinimetrics use only):

Protocol(s)
(Title and Number)

	
  Start
  Date:

  	
  Stop Date:

  

Project
Contact(s):

CLINIMETRICS
RESEARCH CANADA, INC.

	
  Administrative Contact (contract)

  	
   

  	
  Technical Contact

  
	
  Name

  	
   

  	
  Name

  
	
   

  	
   

  	
   

  
	
  Address

  	
   

  	
  Address

  
	
  Phone

  	
   

  	
   

  
	
   

  	
   

  	
  Phone

  
	
  Fax

  	
   

  	
  Fax

  
	
  E-Mail

  	
   

  	
  E-Mail

  

URIGEN
HOLDINGS, INC.

	
  Administrative Contact (contract)

  	
   

  	
  Technical Contact

  
	
  Name

  	
   

  	
  Name

  
	
   

  	
   

  	
   

  
	
  Address

  	
   

  	
  Address

  
	
  Phone

  	
   

  	
   

  
	
   

  	
   

  	
  Phone

  
	
  Fax

  	
   

  	
  Fax

  
	
  E-Mail

  	
   

  	
  E-Mail

  

 

	
  Budget Amount:

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Budget Conditions:

  	
   

  	
  o

  	
   

  	
  Fee-for-Service

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  o

  	
   

  	
  Payment Schedule (specify):

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  o

  	
   

  	
  Other (specify):

  

 

	
  CLINIMETRICS RESEARCH CANADA, INC.

  	
   

  	
  URIGEN HOLDINGS, INC.

  
	
  By:

  	
   

  	
   

  	
   

  	
  By:

  	
   

  	
   

  
	
  Title:

  	
   

  	
  Chief Business Officer

  	
   

  	
  Title:

  	
   

  	
   

  
	
  Date:

  	
   

  	
   

  	
   

  	
  Date:

  	
   

  	
   

  

 

EXHIBIT
B

WORK
ORDERS

(in the form of Exhibit A)Exhibit 10.38

	
  

  

 

August 1, 2006

	
  Terry Nida

  
	
  Urigen

  
	
  211 Ferry Landing Road

  
	
  Cordele, GA 31015

  

 

Re:
Project: READY - SET - GO

Dear Terry,

We are pleased to present to you our final proposal to serve as Urigen’s
virtual marketing group. In this role NCI will conduct a US situational
assessment and product strategy and create and implement a commercialization
plan for Urigen’s product for use in the treatment of chronic pelvic pain and
urgency. Subsequent to these efforts, NCI will also develop a comprehensive
portfolio strategy to maximize the value to Urigen. The proposal objectives are
defined as specific phases below.

Services

Navigant Consulting (“NCI”) understands that its work on this
engagement is to be performed at the request of Urigen (“Client”) on a
best-efforts basis. Services rendered by Navigant Consulting will address the
following:

PHASE
I:     US Situational Assessment and
Product Strategy

·                            Using
secondary literature, internal databases and phone interviews and web surveys
with US key opinion leaders, caregivers (Urologists, Gynecologists and
Urogynecologists), payers, and patient advocacy groups, conduct a US
situational assessment of the chronic pelvic pain and urgency market and
forecast US market opportunities for Urigen’s product under expected,
optimistic and conservative scenarios. Forecasting considerations include:

—                     Patient
population (incidence, prevalence, segmentation, etc.)

—                     Market
size and growth projections

—                     Current
and emerging treatment trends and decision points

—                     Market
drivers and unmet needs

—                     Current
competitive landscape analysis

—                     Pipeline
products in development

—                     Reimbursement
issues

—                     Market
opportunities and threats

—                     Urigen’s
product SWOT

—                     Revenue
forecast scenarios (conservative, expected, optimistic)

·                            Based
on the results of the situational analysis, develop a strategy for Urigen’s
product. Product strategy components include but are not limited to:

—                     Target
markets

—                     Target
customers

—                     Preliminary
positioning and messaging strategy

—                     Preliminary
product lifecycle management strategy

—                     Prelininary
pricing recommendation for lead indication

—                     Preliminary
product revenue forecast

—                     Other
strategic product commercialization considerations

Timing:                 8-12 Weeks

Estimated Project Cost:                 $125,000

$125,000 - Includes up to 120 physician interviews (50 Urologists, 50
Gynecologists, 20 Urogynecologists), up to 10 payer interviews (public and
private), discussions with advocacy groups (as needed), transcriptions and
comprehensive strategic analysis

PHASE
II: US Commercialization and Launch

·                            Develop
and execute Pre-Launch and Launch plans and activities for Urigen’s product
including strategy development, market analytics and marketing research
planning and execution, medical planning, pricing and reimbursement strategy
and execution. Deliverables from Phase I may supplement aspects of the
Pre-launch and Launch plans. Key activities include:

—                     Attitude
and Usage Assessment

—                     Competitive
Scenario Planning

·                            Competitive
forces analysis

·                            New
entrant defense strategy

·                            Predicted
competitor response analysis

·                            Key
indicators

 2

—                     Customer
Segmentation and Perceptions

·                            Core
customer prioritization

·                            Core
customer size

·                            Key
stakeholder analysis (physicians, payers, patients, patient groups)

·                            Consumer
decision influencers

·                            Switches,
persistency and compliance

·                            Decision
process and key points of influence

·                            External
influencers on patient flow

—                     Positioning
and Branding

·                            Define
brand options and brand equity (compound, competitors)

·                            Develop
branding elements

·                            Develop
claims and label attributes

·                            Define
hierarchy of needs, key demographics, attitudes and behaviors

·                            Define
primary and secondary benefits

·                            Develop
concepts

·                            Test
concepts

·                            Packaging
design and artwork

·                            Global
trademark review (internal and USPTO) and FDA submission

—                     Clinical
and Medical Plan

·                            Define
KOLs

·                            Establish
advisory board

·                            Perform
medical need gap analysis

·                            Develop
phase IIIB program

·                            Develop
phase IV program

·                            Develop
publications strategy

·                            Develop
CME strategy

—                     Pricing
and Reimbursement

·                            Determine
the competitive pricing landscape

·                            Develop
plan to increase value proposition

·                            Finalize
pricing and reimbursement strategy to maximize product opportunities

·                            Define
primary payers and influencers

·                            Establish
payer segmentation

·                            Evaluate
strategies to maximize access, revenues, and profits

·                            Analyze
pharmacoeconomic benefit of product based on target label attributes

—                     Risk
Adjusted and NPV Forecasts

·                            Develop
patient-based forecast

·                            Develop
analogue-based forecast

·                            Evaluate
risk and adjust forecast

·                            Evaluate
new business sources (NRx, Switches)

—                     Targeting
and Segmentation

·                            Identify
and prioritize target customer segments

·                            Understand
key needs by segment

 3
 

·                            Map
current behavior patterns

·                            Identify
desired behaviors

·                            Perform
gap analysis

—                     Messaging

·                            Core
benefit analysis by target customer segment

·                            Message
creation and testing

·                            Launch
message components

—                     Sales
Force Planning

·                            Identification
and negotiation with CSO or strategic partner with specialty sales force

·                            Sales
force structure, size, targeting, frequency, duration of detail, rep qualification

·                            Training
material development

·                            CRM
and sales force effectiveness plan

—                     Product
Launch plan and Execution

·                            Resource
Allocation

·                            Professional
Marketing

·                            Medical
Affairs

·                            Sales
Force

·                            Launch
and Sales Force Training

·                            Public
Relations

·                            Consumer

·                            Distribution

·                            Managed
Care

·                            Performance
Management

Timing:                12-18 months

Estimated
Project Costs:

	
  KOL Advisory
  Board Meeting:

  	
  $20,000

  
	
  Competitor
  Scenario Planning:

  	
  $105,000

  
	
  A&U
  Assessment:

  	
  $90,000

  
	
  KOL Mapping:

  	
  $20,000

  
	
  Positioning
  Study:

  	
  $200,000

  
	
  Patient
  Exploratory Study:

  	
  $75,000

  
	
  Branding
  Development & Testing:

  	
  $160,000

  
	
  Global Trademark
  Review & Submission:

  	
  $5,000-$10,000 / country depending on number

  
	
  Medical Needs
  Gap Analysis:

  	
  $130,000

  
	
  Development of
  clinical trial plan:

  	
  $20,000

  
	
  Development of
  Publication/CME/Medical Education: 

  	
  $60,000 

  

 

 4
 

 

	
  Label
  Attributes:

  	
  $30,000

  
	
  Quantitative
  Pricing Study:

  	
  $150,000

  
	
  Reimbursement
  Analysis:

  	
  $60,000

  
	
  Reimbursement
  Plan:

  	
  $25,000

  
	
  Forecasting:

  	
  $120,000

  
	
  Segmentation
  Study:

  	
  $150,000

  
	
  Pharmacy Study/Distribution:

  	
  $30,000

  
	
  Conjoint
  Messaging Analysis:

  	
  $190,000

  
	
  Concept
  Development & Testing:

  	
  $250,000

  
	
  Packaging Design
  and Artwork:

  	
  $30,000-$50,000

  
	
  Managed Care
  Plan:

  	
  $40,000

  
	
  Sales Force
  Planning

  	
  $285,000

  
	
  Performance
  Management:

  	
  $70,000

  
	
  Launch and Execution
  Plan:

  	
  $300,000

  

PHASE III: Portfolio
Strategy Development

·                            Develop
a portfolio strategy that maximizes value to Urigen. Key activities include:

—                     Identifying
key therapeutic markets (woman’s health, pain management, etc.) and indications

—                     Determine
which segments align with Urigen’s corporate objectives and strategies

—                     Assess
attractiveness of each market segment that aligns with the strategy

i.                            Market
growth, evolution and trends

1.                         Incidence
and prevalence

2.                         Current
treatment regimens

ii.                         Competitive
intensity

iii.                      Target
customer base

iv.                     Unmet
medical needs

1.                         Efficacy
of current and emerging products (where possible using secondary sources and
limited primary interviews)

2.                         Side
effects

3.                         Patient
compliance influencers

4.                         Breadth
of treatment options

5.                         Degree
of satisfaction

—                     Using
weighted scoring and ranking criteria, assess product opportunities in the most
attractive segments

—                     Develop
recommendations for building the franchise portfolio over time

i.                            In-licensing/acquisition
of specific products

ii.                         Initiatives
for internal development or partnerships

 5

Timing: 10-12 weeks

Estimated Project Cost: $200,000 -
$400,000

Navigant Consulting Experience

Navigant Consulting (NCI) experience includes
successful consulting engagements and deep industry experience evaluating
therapeutic markets and launching pharmaceutical products:

·                            15
years of pharmaceutical and therapeutic experience

·                            Involved
in > 40 product launches

·                            Former
industry executives with deep knowledge of pharmaceutical products and markets
(BMS, Johnson & Johnson, Roche, Pfizer, Novo Nordisk, Tyco)

·                            Contact
database with key opinion leaders, clinicians, payers, regulators and patients

·                            450
healthcare consultants in 36 offices

·                            Payer,
Provider and Life Science practices provide access across entire healthcare
value chain

“Navigant has been our virtual marketing organization
for the past 3 years now.”

S.R. - Head, Strategic Marketing, International
Pharmaceutical Company

Select Biographies

Ken Smith, MBA

Mr. Smith is a Director with the Healthcare team at Navigant
Consulting and specializes in strategy development, opportunity assessments,
new product planning, licensing and partnering and market analytics. Life
science clients served include pharmaceutical, biotechnology, drug discovery
and medical device companies. Most recently, Mr. Smith has been Engagement
Manager and Lead Consultant on pain management and endometriosis engagements.
Mr. Smith has worked in the life science industry for 20 years as a
scientist, an industry executive and an experienced consultant. In 2000,
Mr. Smith was a Partner at Front Line Strategic Consulting, which was
acquired by Navigant Consulting in 2003. Prior to Front Line Strategic
Consulting, Mr. Smith consulted for Emergent Consulting, co-founded and
was CEO at BOMdiver Software and was Vice President of Marketing and Sales and
General Manager at GSI Lumonics. Earlier in his career, Mr. Smith was
Marketing Manager and Product Manager for Bio-Rad Laboratories, Research
Associate at Collagen Biomedical and Research Manager at U.C. Davis Medical
Sciences Laboratories.

 6
 

Jay
Martin, MBA

Mr. Martin is an
Associate Director in the Healthcare Practice at Navigant Consulting and has a
breadth of experience in marketing consumer and pharmaceutical products. He has
held positions with Dey Labs, Kellogg Company, Abbott, and Merck KGaA. His
experience includes annual strategic planning and brand operational plans, new
product development and launch, forecasting, budgeting, consumer and direct to
consumer pharmaceutical advertising, media planning and buying, physician
advertising, physician promotional response and detail planning.
Mr. Martin has extensive generic experience in both consumer packaged
goods and pharmaceutical. This experience includes: strategic planning to
maximize brand and generic businesses simultaneously; new product development
and launches; existing product improvements; development and implementation of
packaging changes; forecasting; tactical promotional planning; product line
rationalization and discontinuation.

Jan
Lambert, CMA, CCS-P

Ms. Lambert is a
senior consultant with Navigant Consulting’s healthcare team and has worked for
the past 26 years in healthcare, dealing with process improvement and clinical
duties. Ms. Lambert has over twenty + years of OB-GYN practice management
and billing experience with emphasis on physician education about the
appropriate documentation for E/M visits, operative notes, delivery records,
and observation visits. In her career supporting OB-GYN practices, she
performed urinalysis, blood counts, blood pressures and fetal monitoring;
assisted with office surgical procedures (colposcopies, cryosurgeries,
insertion of IUDs, and endometrial samplings), performed fetal non-stress tests
and was Secretary of the local chapter of the AAMA for two years and attended
the national convention as a representative from the state in 1995 and 1996.

Eduardo
Schur, MBA

Eduardo Schur is Director
in the Healthcare Group at Navigant Consulting. He is an experienced marketing
professional with specific expertise in the pharmaceutical industry. Prior to
joining Navigant Consulting, Mr. Schur was Vice President of Marketing for
Plavix, a blockbuster brand for Bristol Myers Squibb. His responsibilities
included strategy, business planning, business development and professional
marketing. In this position, he was responsible for development of a brand
extension and associated launch preparation for the U.S. Mr. Schur has
also held various management positions with Johnson & Johnson, where he
provided marketing and sales strategy and expertise in building brands for
Ortho-McNeil, McNeil Consumer Healthcare and Janssen Pharmaceutica.

Jon
Meyer, MBA, Msc.

Mr. Meyer is an
Associate Director in the Healthcare Practice at Navigant Consulting with 10
years experience in the pharmaceutical industry. For more than 5 years,
Mr. Meyer has managed pharmaceutical, drug delivery and biotechnology
engagements in areas including,

 7
 

oncology, diabetes, pain
management, and cardiovascular disease. He has served as the day-to-day project
lead on numerous product commercialization engagements including opportunity
assessments, pricing and reimbursement analyses, forecasting, competitive
benchmarking, positioning and messaging strategy and clinical trial design and
analysis. Mr. Meyer’s methodological expertise includes market analytics,
modeling/forecasting, primary interviewing/focus group moderation, strategic
planning, and competitive benchmarking. Mr. Meyer holds Masters Degrees in
clinical science and business administration.

Joanne
Toran, MBA, MPH.

Ms. Toran is a
Managing Consultant with the Life Sciences Group at Navigant Consulting. She
has helped clients achieve their goals during engagements involving opportunity
assessments, competitive intelligence, scenario analysis, and corporate
strategic planning. Ms. Toran has participated in a number of engagements
with pharmaceutical, biotechnology, medical device and pharmacy benefit
management companies in areas including cardiovascular quality measures, wound
care product positioning, podiatry product distribution, and new product
development for consumer-driven health plans. Prior to joining Navigant
Consulting, Ms. Toran worked with the Strategic Market Reports division of
Front Line Strategic Consulting marketing key emerging technology and
therapeutic area analyses.

Kathy
Day:

Ms. Day is an expert
in US labeling and prescription drug advertising regulations. With over 30
years in the industry, she has secured initial US labeling approvals for over
20 human prescription drugs and successfully launched over 50  new prescription drugs, including
blockbusters and major brands. Kathy has worked with leading pharmaceutical
companies including Pfizer, Pharmacia, and The Upjohn Company, and has a
demonstrated ability to develop and align regulatory, medical development, and
marketing strategies in support of corporate goals.

Other Terms and Conditions

Consulting Rates: Navigant Consulting
will bill Client for all professional services at established hourly rates plus
related out-of-pocket expenses. For the purpose of this engagement, out-of-pocket
expenses include interview honoraria, line charges, database access and
transcription fees. Travel related expenses are additional and must be approved
by the client. Hourly rates are based upon the experience and skills of the
personnel involved and are subject to adjustments to reflect changes in rates
as officially established by Navigant Consulting, typically on January 1st of each calendar year.

 8

Navigant Consulting Inc. 2006 Hourly Rates:

	
  Managing Director

  	
   

  	
  $

  	
  350

  	
   

  
	
  Director

  	
   

  	
  $

  	
  300

  	
   

  
	
  Associate
  Director

  	
   

  	
  $

  	
  250

  	
   

  
	
  Managing
  Consultant

  	
   

  	
  $

  	
  225

  	
   

  
	
  Senior
  Consultant

  	
   

  	
  $

  	
  200

  	
   

  
	
  Consultant

  	
   

  	
  $

  	
  175

  	
   

  
	
  Analyst

  	
   

  	
  $

  	
  150

  	
   

  

 

Payment:  For Phase I of this engagement, the
client will be responsible for payment of 50% of total phase I expenses
(estimated at $12,500) upon implementation of the engagement. The remainder of
Phase I project expenses (estimated at $12,500) is due upon delivery of the final
situational assessment. The remainder of professional fees is due upon client’s
receipt of mezzanine financing or at the end of Ql 2007, whichever comes first.

Given that NCI is conducting Phase I of this engagement at risk, Urigen
agrees to engage NCI for all subsequent commercialization and launch and
portfolio strategy development activities that are the responsibility of Urigen
related to U101.

For Phases II and III, the client will be invoiced monthly and is
responsible for payment of invoices rendered by Navigant Consulting. Payment of
professional fees and expenses is due within 30 days of the invoice date.

For all invoices, interest will accrue thereafter at the prime rate as
set from time to time by the American National Bank of Chicago plus 2%. Payment
of our invoices is not contingent upon results. Navigant Consulting does not
warrant or predict results or developments in this matter.

Client agrees that it will review invoices upon receipt of each invoice
and will advise Navigant Consulting within 30 days of the receipt of each
invoice as to any objection Client has with the form or substance of the
invoice. Lack of timely objection to an invoice shall evidence Client agreement
to pay the invoice in full. Navigant Consulting reserves the right to terminate
this engagement if payment of fees and expenses billed is not made within 60
days of the invoice date. If such termination occurs, Navigant Consulting shall
be entitled to payment for all services performed prior to termination.

Confidentiality:  Navigant Consulting acknowledges that all
materials disclosed to it by Client, and the work it provides to Client, are
confidential and proprietary. Navigant Consulting will abide by all reasonable
restrictions placed by Client on the dissemination of such materials and work.
In the event that Navigant Consulting is served with a subpoena or other legal
document requesting the disclosure of such materials or work, Navigant
Consulting will promptly advise Client of same and Navigant Consulting will
cooperate

 9
 

with all reasonable and lawful requests by Client to prevent the
disclosure of confidential and/or proprietary information pursuant to such
subpoena or other request.

Conflicts of Interest:  Based on the names of the parties you
have provided we are not aware of circumstances that constitute a conflict of
interest or that would otherwise impair our ability to provide objective
assistance. Our determination of conflicts is based primarily on the substance
of our work as opposed to the parties involved. Navigant Consulting may be
retained by parties with interests that may not be consistent with those of
Client. Navigant Consulting reserves the right to accept engagements by other
parties consistent with Navigant Consulting internal, past practices.

Liability:  The total liability of Navigant
Consulting, its subsidiaries, officers, employees and agents for all claims of
any kind arising out of this engagement, whether in contract, tort or
otherwise, shall be limited to the total fees paid to Navigant Consulting on
this engagement. Neither party shall in any event be liable to the other for
any indirect, consequential or punitive damages. Navigant Consulting shall not
be liable for any loss or destruction of any valuable documents provided to
Navigant Consulting and Client shall be responsible for insuring such documents
against loss or destruction.

Taxes:  Client shall be responsible for and
hereby agrees to pay any sales or use taxes assessed by local, state, federal
or foreign authorities, which are or may be imposed in the future by reason of
the services provided by Navigant Consulting on this engagement. This provision
shall not apply to any income tax assessed against Navigant Consulting.

Resolution of Disputes:  Neither Navigant Consulting nor Client
shall institute a proceeding before any court to resolve any controversy or
claim (“dispute”) arising out of or relating to this engagement until the
parties have sought to resolve the dispute through direct, good faith, and
negotiation. The key principals of each party shall participate in such direct
negotiations. If the dispute is not resolved within 30 days after a written
demand for direct negotiations the parties shall attempt to resolve the dispute
through non-binding mediation. If the parties do not promptly agree on a
mediator, either party may request that a mediator be appointed by
JAMS/Endispute. All mediation proceedings hereunder shall be held in
California. All matters raised or discussed in the course of the mediation will
not be admissible as evidence in connection with any litigation that may be
instituted by the parties if the dispute is not resolved. If the mediator is
unable to facilitate a settlement of the dispute within a reasonable period of
time, as determined by the mediator, the mediator shall issue a written
statement to the parties to that effect and the aggrieved party may then seek
any form of relief to which it may be entitled. Unless otherwise agreed the
mediator’s fees and expenses shall be paid by the party initiating the
mediation.

Independent Contractor Status:  Navigant Consulting shall provide
services to Client as an independent contractor, and none of its employees or
independent contractors shall be an employee of Client. None of Navigant
Consulting’s employees or independent contractors shall have or claim any right
arising from Client employee status.

 10
 

Governing Law:  This Agreement shall be construed and
interpreted according to, and the rights of the parties shall be governed by,
the laws of the State of California.

Entire Agreement:  This Agreement constitutes the complete
and final expression of the agreement of the parties and is intended as a
complete and exclusive statement of the terms of their agreement and supersedes
all prior and contemporaneous offers, promises, representations, negotiations,
discussions, communications, and agreements which may have been made in
connection with the subject matter hereof.

If you wish to engage us to provide the services outlined in this
Agreement please sign in the space provided below and return an executed
original to us. We will commence work upon receipt of an executed original of
this letter indicating your acceptance of the terms and conditions outlined
herein.

We look forward to providing our services in connection with this matter.
If you have any questions, please do not hesitate to call me.

 

	
  Very truly yours,

  	
   

  	
   

  	
   

  	 

	
   

  	
   

  	
   

  	
   

  	 

	
  Navigant Consulting, Inc.

  	
   

  	
   

  	
   

  	 

	
   

  	
   

  	
   

  	
   

  	
   

  	 

	
   

  	
   

  	
   

  	
   

  	
   

  	 

	
  By:

  	
  Ken Smith

  	
   

  	
  Date:

  	
  8/2/06

  	
   

  	 

	
   

  	
  Director

  	
   

  	
   

  	
   

  	 

	
   

  	
   

  	
   

  	
   

  	
   

  	 

	
   

  	
  /s/ Ken Smith

  	
   

  	
   

  	
   

  	 

	
   

  	
   

  	
   

  	
   

  	
   

  	 

	
   

  	
   

  	
   

  	
   

  	
   

  	 

	
   

  	
   

  	
   

  	
   

  	
   

  	 

	
  Agreed
  to and Accepted: 

  	
  Urigen Holdings Inc.

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  By:

  	
  /s/ Martin Shmagen

  	
   

  	
  Date:

  	
  8/2/06

  	
   

  
	
   

  	
  Martin Shmagen

  	
   

  	
   

  	
   

  
											

 

 

 11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00120-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00120-of-00352.parquet"}]]